Ascendis Pharma A (ASND) - News Archive

Ascendis Submits Marketing Authorisation Application for TransCon CNP to Treat Achondroplasia in Children COPENHAGEN, Denmark On October 8, 2025, Ascendis Pharma A/S (Nasdaq: ASND) announced a significant development in...

Uncovering Ascendis Pharma s Promising Data Presentations and Revenue Boom Ahead of ENDO 2025 In a significant development for Ascendis Pharma A/S (Nasdaq: ASND), the company recently announced a lineup of pivotal oral...

The realm of endocrinology is under constant evolution, spearheaded by innovative research and groundbreaking clinical trials. Recently, the InsiGHTS trial made an indelible impact on our understanding and treatment of...

COPENHAGEN, Denmark, Dec. 19, 2024 Ascendis Pharma A/S (Nasdaq: ASND) has announced the impressive milestone of making YORVIPATH (palopegteriparatide) commercially available by prescription in the United States, marking...

In a remarkable presentation at the American Society for Bone and Mineral Research (ASBMR) 2024 conference, Ascendis Pharma A/S unveiled compelling three-year data from their ongoing Phase 2 PaTH Forward Trial, revealin...

The Efficacy of TransCon CNP (Navepegritide) in Clinical Management: Insights from the Pivotal ApproaCH Trial The recent Pivotal ApproaCH Trial investigating the use of TransCon CNP (Navepegritide) has yielded promising...

News U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for YORVIPATH in the United States for the treatment of hypoparathyroidism in adults In a significant development for the treatment of hyp...

Ascendis Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative therapies for rare endocrine diseases, has announced a significant financial milestone. The company has entered i...

Ascendis Pharma A/S (Nasdaq: ASND) has recently announced significant advancements in the field of achondroplasia and chronic hypoparathyroidism. The company presented data from the Phase 2 ACcomplisH trial of TransCon...

Ascendis Pharma Presents New Data on Promising Treatments at ASCO 2024Ascendis Pharma, a biopharmaceutical company based in Denmark, has recently presented new data and updated results from its clinical trials at the Am...

Ascendis Pharma Extends FDA Review, Expands Market Reach with YORVIPATH, and Unveils Vision 2030In a series of significant developments, Ascendis Pharma A/S (Nasdaq: ASND) has strategically extended its market presence...

Improving Renal Function in Adults with Chronic Hypoparathyroidism: TransCon PTH Shows Promising Results According to Ascendis Pharma s Phase 3 PaTHway TrialCOPENHAGEN, Denmark, May 13, 2024 - Ascendis Pharma A/S (Nasda...

The renowned pharmaceutical organization, Ascendis Pharma A/S, has recently achieved significant strides in the therapeutic advancement for patients suffering from chronic hypoparathyroidism and growth hormone deficienc...

Ascendis Pharma Launches 2nd TransCon Product: YORVIPATH Now Available in Germany and Austria for Adults with Chronic HypoparathyroidismCOPENHAGEN, Denmark - Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical compa...

In a groundbreaking announcement, Ascendis Pharma A/S unveiled its strategic roadmap, Vision 2030, at the prestigious 42nd Annual J.P. Morgan Healthcare Conference. The Danish biopharmaceutical company, listed on Nasdaq...

Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon CNP (Navepegritide) at 100g/kg/weekCOPENHAGEN, Denmark, Dec. 20, 2023 - Ascendis Pharma A/S...

Recently, groundbreaking results from the Phase 3 foresiGHt trial have shed light on the incredible potential of TransCon hGH (lonapegsomatropin), an innovative treatment for adults suffering from growth hormone deficie...

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan: Teijin to Lead Development and Commercialization of TransCon TherapiesIn a major strategic move, Ascendis Pharma has joined forces with Teiji...